Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adaptimmune Therapeutics's gross profit for the
three
months ended in Jun. 2025 was $11.18 Mil. Adaptimmune Therapeutics's gross profit for the trailing twelve months (TTM) ended in Jun. 2025 was $61.71 Mil.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Adaptimmune Therapeutics had a gross margin of 81.71% for the quarter that ended in Jun. 2025 => Durable competitive advantage
Adaptimmune Therapeutics Gross Profit Related Terms
Adaptimmune Therapeutics Gross Profit Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADAPY vs BCLI, APRE, JSPR: Gross Profit Comparison
For the Biotechnology subindustry, Adaptimmune Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adaptimmune Therapeutics Gross Profit vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's Gross Profit distribution charts can be found below:
* The bar in red indicates where Adaptimmune Therapeutics's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $61.71 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Adaptimmune Therapeutics (ADAPY) has a Gross Profit of $61.71 Mil as of Jun. 2025. Gross Profit equals net sales less total cost of goods sold. View historical data on Adaptimmune Therapeutics and its competitors.
Is Adaptimmune Therapeutics' Gross Profit too high?
Adaptimmune Therapeutics' current Gross Profit is $61.71 Mil.
How does Adaptimmune Therapeutics' Gross Profit compare to BCLI and APRE?
Adaptimmune Therapeutics' Gross Profit of $61.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Biotechnology company?
A good Gross Profit depends on the Biotechnology industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Adaptimmune Therapeutics and its competitors. Adaptimmune Therapeutics's current Gross Profit is $61.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptimmune Therapeutics stock overvalued right now?
Adaptimmune Therapeutics (ADAPY) has a current Gross Profit of $61.71 Mil. The current Gross Profit is $61.71 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Adaptimmune Therapeutics (ADAPY), the current Gross Profit is $61.71 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its product pipelines include ADP-600 [PRAME] and ADP-520 [CD70].
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADAPY has been successfully added to your 
